Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
GS010 - LUMEVOQ
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
22 Feb 2021 - 25 Feb 2021
4th Annual Gene Therapy for Rare Disorders – virtual
18 Feb 2021
OIS Gene Therapy Innovation Showcase – virtual
13 January 2021
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®
20 Feb 2021 - 23 Feb 2021
47th NANOS Annual Meeting – Virtual Meeting
10 December 2020
GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
13 Nov 2020 - 15 Nov 2020
American Academy of Ophthalmology 2020 – Virtual
03 November 2020
GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency
06 Nov 2020
Eyecelerator 2020 – Virtual Conference
02 Nov 2020 - 05 Nov 2020
World Orphan Drug Congress Europe 2020 – Live Digital
26 Oct 2020 - 28 Oct 2020
4th Annual Gene Therapy for Rare Disorders Europe – Virtual
View previous 9 articles
1
…
3
4
5
6
7
8
9
10
11
12
13
…
16
View next 9 articles
Go back to the page of the page